The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease
Olveira, Antonio (Hospital Universitario La Paz (Madrid))
Augustin Recio, Salvador ![Identificador ORCID](/img/uab/orcid.ico)
(Hospital Universitari Vall d'Hebron)
Benlloch, Salvador ![Identificador ORCID](/img/uab/orcid.ico)
(Hospital Arnau de Vilanova (València))
Ampuero, Javier ![Identificador ORCID](/img/uab/orcid.ico)
(Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Suárez-Pérez, Jorge Alonso (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Armesto, Susana ![Identificador ORCID](/img/uab/orcid.ico)
(Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Vilarrasa-Rull, Eva
(Institut d'Investigació Biomèdica Sant Pau)
Belinchón, Isabel
(Universidad Miguel Hernández de Elche)
Herranz Pinto, Pedro (Hospital Universitario La Paz (Madrid))
Crespo García, Javier
(Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Guimerá, Francisco (Hospital Universitario de Canarias (La Laguna))
Gómez-Labrador, Lara (Novartis Farmacéutica (Madrid))
Martín, Víctor (Novartis Farmacéutica (Madrid))
Carrascosa, José Manuel
(Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona
Fecha: |
2023 |
Resumen: |
Interleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent and severe in patients with psoriasis. In liver inflammation, IL-17 is mainly produced by CD4+ T (TH17) and CD8+ T cells (Tc17), although numerous other cells (macrophages, natural killer cells, neutrophils and Tγδ cells) also contribute to the production of IL-17. In hepatocytes, IL-17 mediates systemic inflammation and the recruitment of inflammatory cells to the liver, and it is also implicated in the development of fibrosis and insulin resistance. IL-17 levels have been correlated with progression from MAFLD to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Clinical trials have shown that inhibiting IL-17A in patients with psoriasis could potentially contribute to the improvement of metabolic and liver parameters. A better understanding of the key factors involved in the pathogenesis of these chronic inflammatory processes could potentially lead to more efficient treatment for both psoriasis and MAFLD, and help to develop holistic strategies to improve the management of these patients. |
Derechos: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by.ico) |
Lengua: |
Anglès |
Documento: |
Article ; recerca ; Versió publicada |
Materia: |
Psoriasis ;
Metabolic-associated fatty liver disease ;
MAFLD ;
IL-17 ;
IL-17A |
Publicado en: |
Life, Vol. 13 (february 2023) , ISSN 2075-1729 |
DOI: 10.3390/life13020419
PMID: 36836776
El registro aparece en las colecciones:
Artículos >
Artículos de investigaciónArtículos >
Artículos publicados
Registro creado el 2023-03-02, última modificación el 2024-06-07